SCHEMBL964216

SCHEMBL964216

Cc1nn(C)c(-n2ccc3cc(Cl)ccc32)c1/C=C/C(=O)NS(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 11/20 0.46
HDAC1 Q13547 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
KDM1A O60341 1/20 0.40
CNR1 P21554 1/20 0.39
PTGER3 P43115 4/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
PTGFR P43088 2/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
MMP1 P03956 1/20 0.37
MMP2 P08253 1/20 0.37
MMP9 P14780 1/20 0.37
MMP8 P22894 1/20 0.37
MMP13 P45452 1/20 0.37
PTGER1 P34995 1/20 0.37
PTGER4 P35408 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL964218 1.00 PPARG (0.46) PPARGHDAC1HDAC8KDM1ACNR1
SCHEMBL965340 0.92 FLT1 (0.40) PPARGCNR1PTGER3MAPTPTGFR
SCHEMBL965338 0.92 FLT1 (0.40) PPARGCNR1PTGER3MAPTPTGFR
SCHEMBL964366 0.92 PTGER3 (0.44) PTGER3MAPTPTGFRPTGER1PTGER4
SCHEMBL964365 0.92 PTGER3 (0.44) PTGER3MAPTPTGFRPTGER1PTGER4
SCHEMBL965316 0.89 PTGER3 (0.40) PPARGHDAC1HDAC8PTGER3MAPT
SCHEMBL965317 0.89 PTGER3 (0.40) PPARGHDAC1HDAC8PTGER3MAPT
SCHEMBL962596 0.88 PTGER3 (0.41) PTGER3MAPTPTGFRPTGER1PTGER4
SCHEMBL962598 0.88 PTGER3 (0.41) PTGER3MAPTPTGFRPTGER1PTGER4
SCHEMBL27793940 0.87 PPARG (0.37) PPARGHDAC1HDAC8PTGER3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-01-13 US disclosed
EP-2118066-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA Takeda Pharmaceutical Company Limited (JP) 2009-11-18 EP disclosed
WO-2008099794-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-21 WO disclosed
US-20080194617-A1 Fused ring compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194617-A1 Fused ring compound SLC5A1, SLC5A2, GPR119 PPARG 248/4885HDAC1 108/4885HDAC8 330/4885
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA PPARA, PPARD, PPARG PPARG 3/4885HDAC1 338/4885HDAC8 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.